857066-90-1|TMC353121|TMC353121|MFCD18633233-范德生物科技公司

TMC353121

NMR下载 COA and HPLC MSDS下载
names：
TMC353121
CAS号：
857066-90-1
MDL Number： MFCD18633233
MF(分子式)： C32H42N6O3 MW(分子量)： 558.71
EINECS:No data available Reaxys Number:No data available
Pubchem ID:11249932 Brand:BIOFOUNT

TMC353121(857066-90-1)是有效的RSV融合抑制剂。TMC353121的活性概况与JNJ-2408068的概况相同。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000869-10mg	10mg	98%	¥ 2636.00	¥ 2636.00		2-3天	- +	¥ 0.00
YZM000869-5mg	5mg	98%	¥ 1360.00	¥ 1360.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	TMC353121(857066-90-1);TMC-353121;TMC 353121
英文别名	TMC353121,857066-90-1
CAS号	857066-90-1
SMILES	OC1=CC=C(C)N=C1CN2C3=CC(CNC4=CC(C)=CC=C4CCCO)=CC=C3N=C2NCCCN5CCOCC5
Inchi	InChI=1S/C32H42N6O3/c1-23-6-9-26(5-3-16-39)28(19-23)34-21-25-8-10-27-30(20-25)38(22-29-31(40)11-7-24(2)35-29)32(36-27)33-12-4-13-37-14-17-41-18-15-37/h6-11,19-20,34,39-40H,3-5,12-18,21-22H2,1-2H3,(H,33,36)
InchiKey	DKORMNNYNRPTBJ-UHFFFAOYSA-N
分子式 Formula	C32H42N6O3
分子量 Molecular Weight	558.71
闪点 FP	451.2±37.1 °C
熔点 Melting point	208℃
沸点 Boiling point	822.4±75.0 °C at 760 mmHg
Polarizability极化度	63.5±0.5 10-24cm3
密度 Density	1.3±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±3.1 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度50 mg/mL(89.49 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)
性状	粉红色到红色固体粉末
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

TMC353121(857066-90-1)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

TMC353121(857066-90-1) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:TMC353121(857066-90-1),TMC353121试剂,TMC353121抑制剂,TMC353121的作用,TMC353121的纯度,TMC353121的合成,TMC353121的含量,TMC353121的生产,TMC353121的使用,TMC353121的MSDS,TMC353121的效果,TMC353121的外观

产品说明	TMC353121(857066-90-1) 是一种有效的呼吸道合胞病毒 (RSV) 融合的抑制剂，pEC50是 9.9
Introduction	TMC353121(857066-90-1) is a potent respiratory syncytial virus (RSV) fusion inhibitor withpEC50of 9.9.
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus

Respiratory Syncytial Virus Disease: Prevention and Treatment(Challenges and Opportunities for Respiratory Syncytial Virus Vaccines,2013)

Evaluation of Antiviral Efficacy Against Human Respiratory Syncytial Virus Using Cotton Rat and Mouse Models(Antiviral Methods and Protocols,2013)

Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins
Abstract:The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of infection. G targets the ciliated cells of the airways, and F causes the virion membrane to fuse with the target cell membrane. The F protein is the major target for antiviral drug development, and both G and F glycoproteins are the antigens targeted by neutralizing antibodies induced by infection. In this chapter, we review the structure and function of the RSV surface glycoproteins, including recent X-ray crystallographic data of the F glycoprotein in its pre- and postfusion conformations, and discuss how this information informs antigen selection and vaccine development.

Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.Bonfanti JF;Roymans D Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
Abstract:Human respiratory syncytial virus (hRSV) is a significant cause of respiratory illness in at-risk pediatric patients, immunocompromised adults and the elderly. No vaccine is currently available for the virus and treatment options are limited to the prophylactic treatment of at-risk infants with the mAb palivizumab (Synagis) and to therapeutic intervention with the nucleoside analog ribavirin (Rebetol). The clinical use of these agents is limited and a need exists for more effective treatment for the at-risk population. The merging of viral and cellular membranes is a crucial event in the hRSV life cycle that enables the virus to enter a host cell. The multistep fusion process is facilitated by the substantial refolding of a trimeric class I fusion protein (F protein), which is the main target of fusion inhibitors. Several small-molecule fusion inhibitors have been discovered, of which some have progressed significantly in the drug development process. BTA-9881 (Biota Holdings Ltd/MedImmune) and TMC-353121 (Johnson & Johnson) are the most advanced of this drug class. In addition, progress has been made in the development of next-generation antibodies such as motavizumab (Numax; MedImmune).

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开